priority meds glp 1 reviews MCT2D Pharmacological interventions for obesity in
Description
high discontinuation rates (e.g., 50-67% at 1 year and 85% at 2 years 5-8 ) that may relate to side effects, costs, variable individual efficacy, or patient preferences 5,9
[1] The oral formulation of semaglutide (Rybelsus) follows similar elimination kinetics to the injectable form despite the different route of administration
Steady-release patches to support appetite regulation, energy, and weight balancenaturally and without pills
Bad breath is reported occasionally among GLP-1 users but is not listed as a major side effect in clinical trials
doi:10.2967/jnumed.106.038679 80
The presence of GLP-1R in hepatocytes, however, remains a subject of debate
